In contrast, the addition of CTLA-4 blockade enhanced antitumor activity, with combination therapy inducing objective tumor regression and more durable disease stabilization, in line with results from larger retrospective and phase II studies [6,10,11,21]. This evidence concerns the gene CTLA4 and neoplasm.